Historically,
VIG was indicated, not recommended, or contraindicated
for the following conditions:
VIG Administration
Indicated
•
Accidental implantation (extensive lesions)
ï
Eczema Vaccinatum
ï
Generalized vaccinia (most instances)
ï
Progressive vaccinia
Indicated
ï
Accidental implantation (mild substances)
ï
Erythema Multiforme
ï
Encephalitis post-vaccination
Contraindicated
ï
Vaccinia
Keratitis
Concomitant
Use with Vaccination
In some instances, VIG was given concomitantly with
vaccination to “prevent” complications in
a susceptible person. Not enough is known about this
use to recommend it
Dosage
When it was used in the 1950’s-1970’s, the
dosage of VIG varied. In general an initial dose of
0.6ml/kg body weight was injected intramuscularly and
subsequent administration determined by the course of
illness.
In severe cases of eczema vaccinatum and progressive
vaccinia as much as 1-10 mg/kg were used. These large
doses were split into smaller units, and injected at
multiple sites spread out over time.
Frequency of Use
Data from a CDC survey indicates that VIG was administered
for these conditions at a rate of 47 uses per 47 million
primary vaccinees and 2 uses per million revaccinees.
